TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
Status:
Completed
Trial end date:
2019-03-30
Target enrollment:
Participant gender:
Summary
This is an open label phase II clinical trial to determine the efficacy, toxicity, and safety
of TAK-228 plus tamoxifen in patients with newly diagnosed ER-positive, HER2-negative breast
cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Jenny C. Chang, MD The Methodist Hospital Research Institute